Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

摘要: Abstract Background: Acute exacerbation of chronic bronchitis (AECB) places tremendous burden on patients, providers, employers, and health care systems. Objective: The purpose this paper is to (1) review the clinical, patient-reported, economic measures used evaluate disease treatment effectiveness in AECB clinical trials (2) propose a guide for selecting study end points that will help capture all relevant outcomes. Methods: Two literature searches PubMed database were conducted identify studies these studies. Results: Previous have focused primarily clinician-assessed outcomes, which do not full impact patients' lives. Reporting mechanisms most been inconsistent, limiting ability compare information or interpret differences. given limited attention patient-reported outcomes implications AECB. Patient-reported such as speed symptom relief work productivity are important parameters assessing provide practical evaluation. Conclusions: Additional research needed develop, examine, validate indirect costs Measuring economic, patients using standardized methods may lead clearer understanding role, effectiveness, cost-effectiveness antibiotic treatment.